Redeye updates its view on Acarix following its Q3 report, showing lower revenues than anticipated. However, the company continues to demonstrate positive US momentum, with 20 new CADScor systems installed and rising patch utilisation. Recent announcements around long-term prospects, including advancements in reimbursement and a first IDN order, position Acarix for an exciting 2025.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/